The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Shestakova M.V.

Institut diabeta Éndokrinologicheskogo nauchnogo tsentra, Moskva

Khalimov Iu.Sh.

Pervaia kafedra terapii (usovershenstvovaniia vracheĭ) Voenno-meditsinskoĭ akademii im. S.M. Kirova, Sankt-Peterburg

Hypoglycemia in patients with type 2 diabetes mellitus: Safe solution of the dangerous problem

Authors:

Shestakova M.V., Khalimov Iu.Sh.

More about the authors

Journal: Therapeutic Archive. 2013;85(12): 144‑150

Read: 5207 times

Download PDF (RU)
Contact the author
Table of contents

HYPOGLYCEMIA IN PATIENTS WITH TYPE 2 DIABETES MELLITUS: SAFE SOLUTION OF THE DANGEROUS PROBLEM
HYPOGLYCEMIA IN PATIENTS WITH TYPE 2 DIABETES MELLITUS: SAFE SOLUTION OF THE DANGEROUS PROBLEM

To cite this article:

Shestakova MV, Khalimov IuSh. Hypoglycemia in patients with type 2 diabetes mellitus: Safe solution of the dangerous problem. Therapeutic Archive. 2013;85(12):144‑150. (In Russ.)

МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Classical and new athe­rosclerosis biomarkers in elde­rly patients with type 2 diabetes mellitus. Russian Journal of Preventive Medi­cine. 2025;(3):87-95
Ethnic aspe­cts of risk factors for the type 2 diabetes mellitus deve­lopment in the overweight women of the Pribaikalsky region. Russian Journal of Preventive Medi­cine. 2025;(8):56-62
Asse­ssment of biomarker levels in patients with STEMI, depe­nding on the presence of cardiovascular events. Russian Journal of Preventive Medi­cine. 2025;(8):96-101
Sex and age characteristics of stroke risk factors in patients with type 2 diabetes mellitus. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(8-2):89-97
Possibilities of oral form of cyanocobalamin in pharmacological correction of vita­min B12 defi­ciency deve­loped in patients with type 2 diabetes mellitus during treatment with metformin. Russian Journal of Preventive Medi­cine. 2025;(9):64-69
Rela­tionship between heart rate and patients with type 2 diabetes death. Russian Journal of Preventive Medi­cine. 2025;(11):14-22
Unso­lved dental problems in children with congenital hype­rinsulin. Stomatology. 2025;(6):67-73
Prospects for Nagu­tskaya no. 26 mine­ral water in correction of carbohydrate and lipid meta­bolism in patients with insu­lin resi­stance. Rege­nerative Biotechnologies, Preventive, Digi­tal and Predictive Medi­cine. 2025;(4):20-28
The role of the Diabetes School in increasing compliance of patients with type 2 diabetes to treatment and improving glycemic control. Russian Journal of Preventive Medi­cine. 2026;(1):47-53
Abstract:

The review gives detailed information on the state-of-the-art of hypoglycemia (HG) and the results of its Russian and international trials. It is noted that HG should be now regarded as an extremely undesirable glucose-lowering therapy complication that is closely related to the risk of cardiovascular events and higher mortality rates, worse glycemic control, and poorer quality of life in patients with type 2 diabetes mellitus (T2DM). The priority effective therapy tactics for T2DM is to manage the latter without any risk of HG, which can be implemented by the wide clinical application of incretins, dipeptidyl peptidase-4 inhibitors in particular, which have the glucose-lowering activity comparable with that shown by metformin and sulfonylurea drugs, are practically safe when used as monotherapy and significantly enhance the efficiency of therapy without substantially increasing the risk of severe HG when co-administered with other medications.

Keywords:

type 2 diabetes mellitus
hypoglycemia
glucose-lowering therapy
dipeptidyl peptidase-4 inhibitors

Authors:

Shestakova M.V.

Institut diabeta Éndokrinologicheskogo nauchnogo tsentra, Moskva

Khalimov Iu.Sh.

Pervaia kafedra terapii (usovershenstvovaniia vracheĭ) Voenno-meditsinskoĭ akademii im. S.M. Kirova, Sankt-Peterburg

Close metadata

References:

  1. Frier B.M., Schernthaner G., Heller S.R. Hypoglycemia and cardiovascular risks. Diabetes Care 2011; 34 (Suppl 2): S132-137.
  2. Bonds D.E., Miller M.E., Bergenstal R.M. et al. The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study. BMJ 2010; 340: 4909.
  3. Cryer P.E. Severe hypoglycemia predicts mortality in diabetes. Diabetes Care 2012; 35: 1814-1816.
  4. Desouza C.V., Bolli G.B., Fonseca V. Hypoglycemia, diabetes, and cardiovascular events. Diabetes Care 2010; 33: 1389-1394.
  5. Seaquist E.R., Anderson J., Childs B. et al. Hypoglycemia and diabetes: a report of a workgroup of the American Diabetes Association and the Endocrine Society. Diabetes care 2013; 36 (5): 1384-1395.
  6. Adler G.K., Bonyhay I., Failing H. et al. Antecedent hypoglycemia impairs autonomic cardiovascular function: implications for rigorous glycemic control. Diabetes 2009; 58 (2): 360-366.
  7. Dedov I.I., Shestakova M.V., Aleksandrov A.A. i dr. Algoritmy spetsializirovannoi meditsinskoi pomoshchi bol'nym sakharnym diabetom. Pod red. I.I. Dedova, M.V. Shestakovoi. M 2013; 120.
  8. Zoungas S., Patel A., Chalmers J. et al. Severe hypoglycemia and risks of vascular events and death. N Engl J Med 2010; 363: 1410-1418.
  9. Cryer P.E. Death during intensive glycemic therapy of diabetes: mechanisms and implications. Am J Med 2011; 124: 993-996.
  10. Choudhary P., Amiel S.A. Hypoglycaemia: current management and controversies. Postgrad Med J 2011; 87 (1026): 298-306.
  11. McCoy R.G., Van Houten H.K., Ziegenfuss J.Y. et al. Increased mortality of patients with diabetes reporting severe hypoglycemia. Diabetes Care 2012; 35 (9): 1897-1901.
  12. Tanenberg R.J., Newton C.A., Drake A.J. Confirmation of hypoglycemia in the "dead-in-bed" syndrome, as captured by a retrospective continuous glucose monitoring system Endocr Pract 2010; 16: 244-248.
  13. Lalic N.M. The Case for: Hypoglycemia Is of Cardiovascular Importance. Diabetes Care 2013; 36 (Suppl 2): S264-266.
  14. O'Keefe J.H., Abuannadi M., Lavie C.J., Bell D.S. Strategies for optimizing glycemic control and cardiovascular prognosis in patients with type 2 diabetes mellitus. Mayo Clin Proc 2011; 86 (2): 128-138.
  15. Inzucchi S.E., Bergenstal R.M., Buse J.B. et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012; 35 (6): 1364-1379.
  16. Dedov I.I., Shestakova M.V., Ametov A.S. i dr. Konsensus soveta ekspertov Rossiiskoi assotsiatsii endokrinologov (RAE) po initsiatsii i intensifikatsii sakharosnizhayushchei terapii sakharnogo diabeta 2-go tipa. Sakharnyi diabet 2011; 4: 6-17.
  17. Campbell P.T., Newton C.C., Patel A.V. et al. Diabetes and cause-specific mortality in a prospective cohort of one million U.S. adults. Diabetes Care 2012; 35 (9): 1835-1844.
  18. Tayek J. SUR receptor activity vs. incidence of hypoglycaemia and cardiovascular mortality with sulphonylurea therapy for diabetics. Diabet Obes Metabol 2008; 10 (11) : 1128-1129.
  19. Gangji A.S., Cukierman T., Gerstein H.C. et al. A systematic review and meta-analysis of hypoglycemia and cardiovascular events: a comparison of glyburide with other secretagogues and with insulin. Diabetes Care 2007; 30: 389-394.
  20. Roumie C.L., Hung A.M., Greevy R.A. et al. Comparative effectiveness of sulfonylurea and metformin monotherapy on cardiovascular events in type 2 diabetes mellitus: a cohort study. Ann Intern Med 2012; 157 (9): 601-610.
  21. Donath M.Y., Burcelin R. GLP-1 Effects on Islets: Hormonal, Neuronal, or Paracrine? Diabetes Care 2013; 36 (Suppl 2): S145-S148.
  22. Cahn A., Raz I. Emerging gliptins for type 2 diabetes. Expert Opin Emerg Drugs 2013; 18 (2): 245-258.
  23. Seck T., Nauck M., Sheng D. et al. Safety and efficacy of treatment with sitagliptin or glipizide in patients with type 2 diabetes inadequately controlled on metformin: a 2-year study. J Clin Pract 2010; 64 (5): 562-576.
  24. Arechavaleta R., Seck T., Chen Y. et al. Efficacy and safety of treatment with sitagliptin or glimepiride in patients with type 2 diabetes inadequately controlled on metformin monotherapy: a randomized, double-blind, non-inferiority trial. Diabetes Obes Metab 2011; 13 (2): 160-168.
  25. Rathmann W., Kostev K., Gruenberger J.B. et al. Treatment persistence, hypoglycaemia and clinical outcomes in type 2 diabetes patients with dipeptidyl peptidase-4 inhibitors and sulphonylureas: a primary care database analysis. Diabetes Obes Metab 2013; 15 (1): 55-61.
  26. Kirkman M.S., Briscoe V.J., Clark N. et al. Diabetes in older adults. Diabetes Care 2012; 35 (12): 2650-2664.
  27. Fu A.Z., Qiu Y., Davies M.J., Engel S.S. Initial sulfonylurea use and subsequent insulin therapy in older subjects with type 2 diabetes mellitus. Diabetes Ther 2012; 3 (1): 12.
  28. Barzilai N., Guo H., Mahoney E.M. et al. Efficacy and tolerability of sitagliptin monotherapy in elderly patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial. Bar Curr Med Res Opin 2011; 27 (5): 1049-1058.
  29. Penfornis A., Bourdel-Marchasson I., Quere S., Dejager S. Real-life comparison of DPP4-inhibitors with conventional oral antidiabetics as add-on therapy to metformin in elderly patients with type 2 diabetes: the HYPOCRAS study. Diabetes Metab 2012; 38 (6): 550-557.
  30. Hage C., Brismar K., Efendic S. et al. Sitagliptin improves beta-cell function in patients with acute coronary syndromes and newly diagnosed glucose abnormalities - the BEGAMI study. J Intern Med 2013; 273 (4): 410-421.
  31. Scheen A.J. Cardiovascular effects of dipeptidyl peptidase-4 inhibitors: From risk factors to clinical outcomes. Postgrad Med 2013; 125 (3): 7-20.
  32. Raz I. Guideline approach to therapy in patients with newly diagnosed type 2 diabetes. Diabetes Care 2013; 36 (Suppl 2): S139-144.
  33. Garber A.J., Abrahamson M.J., Barzilay J.I. et al. AACE Comprehensive Diabetes Management Algorithm 2013. J Endocr Pract 2013; 19 (2): 327-336.
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.